PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...

Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company focused on cardiovascular disease treatments, announced that it will present new data on its AAV manufacturing approach at the 28th ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...

Six ASGCT 2026 presentations highlight PackGene advances in scalable AAV manufacturing, analytics, and capsid engineering. HOUSTON, May 5, 2026 /PRNewswire/ -- PackGene Biotech, Inc. announced today ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

CDMO 3PBIOVIAN officials report that the company has launched the AAVion ® platform, a fully integrated adeno-associated virus (AAV) manufacturing solution designed to accelerate gene therapy ...

COLLEGE STATION, Texas and SAN DIEGO, June 16, 2026 /PRNewswire/ -- **Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in ...

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral ...

Good Manufacturing Practice (GMP) compliance in adeno-associated virus (AAV)-based cell and gene therapy development can pose significant challenge, including proving capsid ratios to regulators and ...

Skylark Bio (“Skylark”), a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and ...

School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell platform, GlyTR (pronounced 'glitter'), engineered to target tumor‑associated carbohydrate antigens ...